Certification under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached enclosed) is being deposited with The United States Postal Service with sufficient postage as first class mail in an envelope addressed to The Assistant Commissioner of

Ratents, Washington, D.C. 20231 on October 15, 2004

Ristard J. Streit (Reg. No. 25765)

Name

DOCKET: CU-2561

1617

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: John P. MCKEARN et al

Serial No.: 09/857,994

Group Art Unit:

Filed: June 13, 2001

Examiner:

For: Method of Using an Integrin Antagonist and One or More Antineoplastic

Agents as a Combination Therapy in the Treatment of Neoplasia

THE ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of the first Office Action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Date: October 15, 2001

Signature of Attorney

Richard J. Streit Ladas & Parry

224 South Michigan Avenue

Chicago Illinois 60604

Tel. No. (312) 427-1300

Reg. No. 25765

idsb4oa

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with The United States Postal Service with sufficient postage as first class mail in an envelope addressed to The Assistant Commission Atents, Washington, D.C. 20231 on October 15, 2001

chard J. Streit (Reg. No. 25765) Name

DOCKET: CU-2561

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: John P. MCKEARN et al

Serial No.: 09/857,984

Group Art Unit:

Filed:

June 13, 2001

Examiner:

For:

Method of Using an Integrin Antagonist and One or More Antineoplastic

Agents as a Combination Therapy in the Treatment of Neoplasia

THE ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit herewith patents, publications or other information of which the applicants are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose under 37 CFR 1.56.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

The references submitted herein are listed on PTO-1449 form (modified) enclosed herewith. A copy of each reference listed is being furnished except any duplicate or cumulative patents or publications specified otherwise.

A translation of any foreign language reference, if any, is indicated in PTO-1449 form and being submitted herein if it is readily available. Otherwise it should be construed that such translation is not readily available.

Additional comments, if any, on the relevance of each reference listed are provided as follows:

Also enclosed is a copy of an International Search Report listing the cited references.

The Statement is made on the basis of the information:

	supplied by the inventor(s);
Χ	supplied by an individual associated with the filing and prosecution
	of this application (37 CFR 1.56(c)); or
	in the attorney's file.

Date: October 15, 2001

Signature of Attorne

Respectfully submitted,

Richard J. Streit

Ladas & Parry

224 South Michigan Avenue

Chicago Illinois 60604 Tel. No. (312) 427-1300

Reg. No. 25765